These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12591277)

  • 1. Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemia.
    Tornhamre S; Stenke L; Granzelius A; Sjölinder M; Näsman-Glaser B; Roos C; Widell S; Lindgren JA
    Exp Hematol; 2003 Feb; 31(2):122-30. PubMed ID: 12591277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aberrant expression of active leukotriene C(4) synthase in CD16(+) neutrophils from patients with chronic myeloid leukemia.
    Sjölinder M; Stenke L; Näsman-Glaser B; Widell S; Doucet J; Jakobsson PJ; Lindgren JA
    Blood; 2000 Feb; 95(4):1456-64. PubMed ID: 10666225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
    Mazzacurati L; Pattacini L; Brusa G; Mancini M; Benvenuti M; Barbieri E; Martinelli G; Baccarani M; Greenberger JS; Santucci MA
    Hematol J; 2004; 5(2):168-77. PubMed ID: 15048068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
    Topaly J; Zeller WJ; Fruehauf S
    Leukemia; 2001 Mar; 15(3):342-7. PubMed ID: 11237055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
    Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
    Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
    Song YP; Fang BJ; Wei XD; Zheng S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia.
    Mayerhofer M; Florian S; Krauth MT; Aichberger KJ; Bilban M; Marculescu R; Printz D; Fritsch G; Wagner O; Selzer E; Sperr WR; Valent P; Sillaber C
    Cancer Res; 2004 May; 64(9):3148-54. PubMed ID: 15126353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Overexpression of Shp-2 is associated with the unlimited growth and apoptosis resistance of p210 bcr-abl-mediated chronic myeloid leukemia].
    Zhu XZ; Yu YZ; Fang YM; Liang Y; Lü QH; Xu RZ
    Zhonghua Yi Xue Za Zhi; 2005 Jul; 85(27):1903-6. PubMed ID: 16255985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
    Jiang X; Saw KM; Eaves A; Eaves C
    J Natl Cancer Inst; 2007 May; 99(9):680-93. PubMed ID: 17470736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors.
    Kasper B; Fruehauf S; Schiedlmeier B; Buchdunger E; Ho AD; Zeller WJ
    Cancer Chemother Pharmacol; 1999; 44(5):433-8. PubMed ID: 10501919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib restores expression of CD62L in BCR-ABL-positive cells.
    Fruehauf S; Topaly J; Schad M; Paschka P; Gschaidmeier H; Zeller WJ; Hochhaus A; Ho AD
    J Leukoc Biol; 2003 May; 73(5):600-3. PubMed ID: 12714574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors.
    Jonuleit T; Peschel C; Schwab R; van der Kuip H; Buchdunger E; Fischer T; Huber C; Aulitzky WE
    Br J Haematol; 1998 Feb; 100(2):295-303. PubMed ID: 9488616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
    Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
    Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.
    Jiang X; Forrest D; Nicolini F; Turhan A; Guilhot J; Yip C; Holyoake T; Jorgensen H; Lambie K; Saw KM; Pang E; Vukovic R; Lehn P; Ringrose A; Yu M; Brinkman RR; Smith C; Eaves A; Eaves C
    Blood; 2010 Sep; 116(12):2112-21. PubMed ID: 20574046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells.
    Tamura T; Kong HJ; Tunyaplin C; Tsujimura H; Calame K; Ozato K
    Blood; 2003 Dec; 102(13):4547-54. PubMed ID: 12933588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
    Jin L; Tabe Y; Konoplev S; Xu Y; Leysath CE; Lu H; Kimura S; Ohsaka A; Rios MB; Calvert L; Kantarjian H; Andreeff M; Konopleva M
    Mol Cancer Ther; 2008 Jan; 7(1):48-58. PubMed ID: 18202009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Kriener S; Engels K; Staib P; Griesshammer M; Waller CF; Ottmann OG; Hansmann ML
    Histol Histopathol; 2004 Oct; 19(4):1277-88. PubMed ID: 15375771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.
    Graham SM; Jørgensen HG; Allan E; Pearson C; Alcorn MJ; Richmond L; Holyoake TL
    Blood; 2002 Jan; 99(1):319-25. PubMed ID: 11756187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.